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Abstract Anti-inXammatory therapeutic options for the
topical treatment of skin diseases with inXammatory or
allergic contribution are mostly limited to topical glucocor-
ticoids and calcineurin inhibitors. Both compound classes
induce adverse eVects. Elevation of intracellular cyclic
adenosine monophosphate (cAMP) by inhibition of phos-
phodiesterase 4 was shown to induce potent anti-inXamma-
tory eVects, but the safety proWle of currently available
compounds is not suYcient. A diVerent approach to
increase intracellular cAMP is the substitution of chemi-
cally stabilized cAMP analogues. Bucladesine is a stabi-
lized cAMP analogue with an excellent safety proWle which
had been marketed as topical treatment of impaired wound
healing. In the current study, a novel water free emulsion
containing bucladesine was evaluated for anti-inXamma-
tory eVects. In the arachidonic acid induced ear oedema
model in mice, single or multiple administration of an
emulsion containing 1.5% was capable of signiWcantly
reducing the inXammatory oedema. The data indicate that
bucladesine represents an interesting treatment option for
skin diseases where an anti-inXammatory activity is indi-
cated. Due to the established clinical safety, this agent may
bridge the gap between potent agents such as glucocorti-
coids or calcineurin inhibitors and emollients without
active compounds.
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Introduction
Cyclic adenosine monophosphate (cAMP) plays an impor-
tant regulatory role in virtually all cell types involved in the
pathophysiology of allergic and inXammatory diseases.
Phosphodiesterase 4 (PDE4) is the major cAMP degrading
isoenzyme in inXammatory and immune cells and in kerati-
nocytes. Inhibition of PDE4 results in broad anti-inXamma-
tory/immunomodulatory action which can be related to
cAMP elevation [15, 19]. PDE4 inhibitors are active in
models of non-immunological skin inXammations such as
the arachidonic acid induced skin inXammation in mice [4],
in models of allergic contact dermatitis in mice, and in
ovalbumin sensitized guinea pigs [14]. Results of early
clinical trials with both topical treatment with cipamfylline
[10] and systemic treatment with atizoram (CP-80,633)
[12] or apremilast [8] demonstrated eYcacy of PDE4 inhib-
itors in atopic dermatitis and psoriasis.
The utility of PDE4 inhibitors is limited by the safety
proWle and drug-induced gastrointestinal adverse eVects
such as nausea or emesis likely represent class eVect toxic-
ity [13]. Due to this toxicity, the maximum tolerated dose is
either sub-therapeutic or at the very bottom of the eYcacy
dose–response curve [7]. RoXumilast is currently the only
selective PDE4 inhibitor marketed for the treatment of
chronic obstructive pulmonary disease, but has a narrow
safety window [18].
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(bucladesine, DB-cAMP) is a membrane permeable stabi-
lized analogue of the endogenous mediator cAMP. Buc-
ladesine is more lipophilic than cAMP and in contrast to
cAMP capable of penetrating cell membranes [3]. It is not
cleaved by PDE but instead acts as an enzyme blocker. In
addition bucladesine interferes with diVerent protein
kinases which are normally activated by cAMP [16]. Buc-
ladesine has undergone in the past clinical developments as
systemic treatment for cardioprotection and as topical treat-
ment to improve wound healing. In Japan, a bucladesine
ointment (Actosin® ointment; Daiichi Pharmaceutical Co.,
Ltd., Tokyo, Japan) was marketed to treat skin ulcers. Clin-
ical studies have shown favourable eVects on diabetic foot
ulcers or decubitus, but the compound was later withdrawn
despite good tolerability [1, 2]. One possible reason for the
withdrawal may be the odour of the cream formulation
which can be related to the hydrolytic cleavage in aqueous
solutions resulting in release of butyric acid [17].
The aim of this study was to evaluate whether buclade-
sine may be capable of suppressing non-immunological
skin inXammation, utilizing the model of arachidonic acid
induced acute inXammation. The experiments aim at proWl-
ing bucladesine as potential new treatment for inXamma-
tory or allergic skin diseases. A further aim was to evaluate
the in vivo activity of a novel water free ointment, devel-
oped to prevent hydrolysis and thus preventing generation
of butyric acid.
Materials and methods
Development of a topical cream formulation
Bucladesine is readily water soluble, but is not stable in
aqueous solutions. At room temperature about 20% of an
aqueous solution of bucladesine is hydrolyzed within
8 days and the speed of hydrolysis is further increased at
pH values below 5 and above 7 (data not shown). It was our
aim to Wnd a water free formulation where bucladesine is
presented in solution to prevent inhomogeneity and insta-
bility resulting from crystal growth or chemical degrada-
tion. To Wnd adequate solvents, a screen was conducted
[Sörensen T (2007) Stabilization of cyclic AMP derivatives
in pharmaceutical preparations for topical application.
Diploma Thesis, Department of Pharmaceutics and Bio-
pharmaceutics, Christian Albrecht University, Kiel, Ger-
many]. The solubility of bucladesine was determined in
diVerent solvents, using a semi-quantitative approach. To
estimate solubility, 8–10 mg of compound was dissolved in
1 g of diVerent solvents by vigorous shaking for 1 h and
visual control of solubilisation. If complete solubilisation
was achieved, the saturation concentration was estimated
by adding step-by-step further small quantities of buclade-
sine until crystalline residues became visible in the vial.
Bucladesine is not well soluble in hydrophobic ingredients
such as silicones, triglycerides or hydrocarbons, but it is
well soluble in propylene glycol, ethylene glycol, and
n-methyl pyrrolidone (Table 1). Silicone Xuid 1250 was
selected as outer phase for an emulsion, while n-methyl
pyrrolidone was selected as inner phase, capable of carry-
ing about 10% of bucladesine. Bucladesine was found to be
stable if dissolved in n-methyl pyrrolidone; no hydrolysis
was observed within 14 days (data not shown). Long term
stability was not conducted for the purpose of this experi-
mental study. The silicone emulsiWer Abil Care 85® (Evo-
nik Goldschmidt GmbH, Essen, Germany) was selected
and, if used at a concentration of 2%, resulted in a stable
emulsion if prepared at lab scale using the IKA laboratory
reactor IKA-LR 250 (IKA Werke GmbH & Co. KG, Stau-
fen, Germany). The emulsion was visibly stable for a
period of >14 days (maximum observation period) and no
sign of hydrolysis, such as increased butyric acid odour,
was observed. The emulsion was also shown to be stable if
tested using a centrifuge assay at up to 5000 rpm for 3 min
[11]. Two diVerent emulsions were selected and prepared
for animal testing. The 0.5% emulsion contained 88% sili-
cone Xuid 1250 and 10% n-methyl pyrrolidone containing
Table 1 Solubility of buclade-
sine in diVerent solvents Solvent Supplier Solubility (mg/g)
ParaYn oil Evonik Goldschmidt GmbH, Essen, Germany <8
Oleyl alcohol Evonik Goldschmidt GmbH, Essen, Germany <8
Miglyol® 812 Caesar & Loretz GmbH, Hilden, Germany <8
Labrafac Lipo WL 1349 Gattefossé GmbH, Weil am Rhein, Germany <8
Silicone Xuid Q7-9120, 20 cSt Dow Corning, Wiesbaden, Germany <9
Silicone Xuid Q7-9120, 12500 cSt Dow Corning, Wiesbaden, Germany <10
n-Methyl pyrrolidone International Speciality Products, Wayne, NJ, USA >112
Propylene glycol Sigma-Aldrich, Munich, Germany >114
Ethylene glycol Sigma-Aldrich, Munich, Germany >151123
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The high concentration emulsion contained 83% silicone
Xuid 12500 and 15% n-methyl pyrrolidone containing
100 mg/g bucladesine, stabilized with 2% Abil Care 85®
resulting in a cream formulation containing 1.5% buclade-
sine.
As reference solution, bucladesine was dissolved imme-
diately prior to the experiment in a mixture of 100 l
DMSO and 900 l water at a Wnal concentration of 5%.
Arachidonic acid induced ear swelling as a model of non-
immunological inXammation
Experimentally naïve male Albino Swiss mice (Laboratory
Animals Breeding, Siaboszów, Poland) weighing 20–30 g
were used in all experiments. The animals were housed in
polycarbonate cages at a controlled temperature (23–25°C)
and humidity (50–60%) with 12 h light/dark cycle (lights
on at 6 h). Tap water and food pellets were available
ad libitum. All experiments were performed after at least
7 days of acclimatization. The experimental protocols were
approved by the Ethical Committee of the Medical Univer-
sity in Lublin (license number 40/2010).
The anti-inXammatory eVect of bucladesine was com-
pared to the respective vehicles and the reference drug
ketoprofen gel 2.5% (Fastum Gel, A. Menarini, Florence,
Italy).
For topical administration of bucladesine as 5% solution,
20 l of drug or vehicle solution was administered onto the
outer surface of both, left and right ears each, 60 min prior
to arachidonic acid challenge. The inXammatory response
was induced by administration of 20 l arachidonic acid
(Sigma-Aldrich, Munich, Germany; 5% in acetone) on the
outer surface of left ears. The right ears were treated with
acetone only to determine the individual diVerences in ear
thicknesses.
To allow for skin penetration of the cream formulations
and based on preliminary experiments with ketoprofen
cream in this model (data not presented), a pre-treatment
time of 3 h was selected. To evaluate the eVect of 0.5 or
1.5% bucladesine cream, an amount of 10 § 1 mg cream
each was spread onto the outer surface of both, left and
right ears using small spatula. A third group of mice was
administered with 2.5% ketoprofen gel. Corresponding
vehicle treatment groups were administered either the
respective cream base without bucladesine or, as reference
for ketoprofen, a cosmetic night cream. To evaluate the
eVect of repeated administration, four separate groups of
mice were dosed twice, i.e., 7 and 3 h before administration
of arachidonic acid with the 0.5 and 1.5% cream or corre-
sponding vehicle. Arachidonic acid or actetone were
administered 3 h after the second cream administration onto
left and right ears, respectively. The ear thickness was mea-
sured with a precise spring-loaded caliper (Mitutoyo, type
7309, Kawasaki, Japan) before and 60 min after application
of arachidonic acid or vehicle.
Statistical analyses
The increase in ear thickness was calculated for each mouse
as the diVerence between left ear thickness before and
60 min after administration of arachidonic acid. To account
for individual variability the diVerence between the right
ear thickness before and 60 min after administration of ace-
tone was subtracted from the arachidonic acid induced
increase in left ear thickness. Mean and standard deviation
(SD) was calculated from single ear oedema values. One-
way analysis of variance (ANOVA) with Dunnett’s post
hoc test or Student’s t test, where appropriate was applied.
Results
Bucladesine, administered topically as water-free cream
formulation, was capable of reducing the arachidonic acid
induced ear swelling. If administered as 0.5% water-free
emulsion, a 10% reduction in ear swelling was reached (not
statistically signiWcant). The eVect was increased if the con-
centration of bucladesine was increased to 1.5%, resulting
in a 28% reduction in ear swelling (P < 0.01%, Fig. 1a).
Twice administration of the cream resulted in an eVect
which was nearly identical to the single administration, i.e.,
10% reduction at 0.5% and 24% reduction at 1.5% buclade-
sine, the later eVect being statistically signiWcant (P < 0.05,
Fig. 1b).
The administration of bucladesine as 5% solution in
DMSO:water only resulted in a modest (18%) reduction in
ear swelling and this eVect failed to reach level of signiW-
cance (P = 0.071, Fig. 2).
As expected, 2.5% ketoprofen gel nearly completely
suppressed the arachidonic acid induced ear swelling
(Fig. 3).
Discussion
Minimal anti-inXammatory treatment of the underlying
residual skin disease by prophylactic application of
immune modulating agents is discussed as an option to pre-
vent the outbreak of acute symptoms in well-controlled
patients [20]. However, therapeutic options are mostly lim-
ited to topical glucocorticoids and calcineurin inhibitors,
two compound classes with tolerability issues especially in
children [6]. While PDE4 enzyme inhibition may be an
interesting immune modulatory option, the safety proWle of
currently known inhibitors is not optimal [5]. Even the123
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ylline induced gastrointestinal adverse eVects, but was at
the same time shown to be pharmacologically active in
patients with atopic dermatitis [10].
An alternative approach to elevate the intracellular
cAMP level is the topical application of a stable analogue
of cAMP. Bucladesine is well tolerated and no PDE4-like
adverse eVects are known from its clinical use as cream for-
mulation [2].
We now show that bucladesine, if administered as water-
free topical cream formulation, is active in an animal model
of acute skin inXammation. The activity of bucladesine in
this model is comparable in size to the activity of the highly
potent PDE4 inhibitor AWD 12–281 in the same model, if
administered at a concentration of 0.3–1%. At higher con-
centrations (3 and 5% ointment), AWD 12–281 was nearly
equipotent to indomethacin, indicating that selective PDE4
inhibitors are more potent than bucladesine [14]. If admin-
istered as 5% solution in DMSO/water, the reduction in ear
oedema did not reach level of signiWcance. These data indi-
cate that an adequate cream formulation is required to
enable the pharmacological eVect of bucladesine. No poten-
tiation of the activity was achieved if the compound was
administered twice, indicating that the eVect is of short
duration.
While in the current study, the arachidonic acid model
was utilized as a simple model of pharmacological activity,
other models of skin inXammations involving Th1- and Th2-
dominated immunological reactions have been shown to be
sensitive to elevation of intracellular cAMP [5]. Therefore,
this treatment strategy may indeed be applicable for the top-
ical treatment of a wide variety of skin diseases. Indeed,
clinical data indicate that elevation of cAMP as therapeutic
principle was active in a human model of acute skin inXam-
mation, the balm of Peru induced skin irritation [9].
In conclusion, bucladesine represents an interesting
treatment option for skin diseases, where an anti-inXamma-
tory activity is indicated. Due to the established clinical
safety, this agent may bridge the gap between potent thera-
peutics such as glucocorticoids or calcineurin inhibitors and
emollients without active compounds.
However the odour of butyric acid represents a chal-
lenge. Despite the fact that the currently developed formu-
lation was found to be stable within the scope of this
investigation, even minimal amounts of butyric acid are
barely tolerable. In future studies, the activity and safety of
a diVerent analogue of cAMP, namely 2-deoxy-cAMP
Fig. 1 Anti-inXammatory eVect of 0.5 and 1.5% bucladesine cream
given (a) 3 h before administration of arachidonic acid [one-way
ANOVA: F(2,27) = 7.062; P = 0.003] or given (b) twice, i.e., 7 and 3 h
before administration of arachidonic acid [one-way ANOVA:
F(2,27) = 3.695; P = 0.0382]. *P < 0.05, **P < 0.01 versus vehicle-
treated mice (one-way ANOVA with Dunnett’s post hoc test)
Fig. 2 Anti-inXammatory eVect of 5% bucladesine given 1 h before
administration of arachidonic acid
Fig. 3 Anti-inXammatory eVect of 2.5% ketoprofen gel given 3 h
before administration of arachidonic acid. ***P < 0.001 versus vehi-
cle-treated mice (Student’s t test)123
Arch Dermatol Res (2012) 304:313–317 317should be evaluated since it can be expected to have a very
similar pharmacological proWle, without the risk of butyric
acid generation.
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